

4DMedical secures \$22.6 million via exercise of options

03 October 2025

Highlights

- 4DMedical secures \$22.6 million via the exercise of deep in-the-money options
- 99.7% of the 4DXOA Options, with an exercise price of \$0.55, were exercised
- 4DMedical's pro forma 30 June 2025 cash balance is \$45.5 million post receipt of this capital
- Further stock options (ASX:4DXO, expiring 31 December 2025) are also currently in-the-money, providing up to \$30.2 million to the balance sheet

Melbourne, Australia, 03 October 2025 – 4DMedical Limited (ASX:4DX, “4DMedical” or the “Company”) a global leader in respiratory imaging technology, today announces the closure of the 4DXOA Option exercise period. 99.73% of these options were exercised, delivering \$22.6 million to the balance sheet.

Working capital secured

The new funds generated from these exercised options, along with the recently announced \$10.0 million strategic investment from Pro Medicus, and the \$6.0 million R&D Tax Incentive receipt, brings the Company's pro forma 30 June 2025 cash balance to \$45.5 million.

These new cash injections extend the funding runway for the Company, ensuring it can execute its strategic and commercial priorities, including:

- Commercialisation and broad adoption of CT:VQ™;
- Penetration of Academic Medical Centres and Health Systems, and Community and Radiology Networks, across the U.S. healthcare market, leveraging the reseller agreement with Philips; and
- Research and product development, including post-FDA clearance CT:VQ™ studies, and broadening the applicable clinical applications with further evidence across the portfolio.

Further options, with a 31 December 2025 expiry date, are also in-the-money

The Company also notes that further opportunities for capital inflows exist via quoted options, ASX:4DXO. There are currently 22.1 million options outstanding with an exercise price of \$1.365, expiring on 31 December 2025, providing up to \$30.2 million to the balance sheet.

4DMedical MD/CEO and Founder Andreas Fouras said:

September has been a great month for 4DMedical and our shareholders. Your strong support has secured the capital required to execute on our commercialisation plans, most notably relating to CT:VQ™.

We are working hard to put together the necessary ingredients for an incredibly successful RSNA 2025 at the end of November, and I look forward to keeping you informed of these wins ahead of that key event.

—ENDS—

Authorised by the 4DMedical Board of Directors.



Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionising respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology**® transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS**®), **CT LVAS**™, and the ground-breaking **CT:VQ**™ solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalised patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com